Shots:
- Novo Nordisk plans to initiate a pivotal P-llla program to evaluate the efficacy and safety of Semaglutide (oral, 14mg, qd) vs PBO in 3,700 patients with AD with the anticipated initiation in H1’21
- The decision follows the evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities
- Semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycemic control in adults with T2D in the US, EU and Japan
Click here to read full press release/ article | Ref: Novo Nordisk | Image: Energy Watch
The post Novo Nordisk to Initiate a P-lll Study of Semaglutide to Treat Alzheimer Disease first appeared on PharmaShots.
